ADRB2 and Parkinson disease: Since we have recently shown how L-DOPA and Droxidopa drugs interact with β2AR [76], our preliminary molecular docking and latest MD simulations findings strengthen the hypothesis that similar binding modes could also be predicted for the other drugs in use for treating patients with Parkinson’s disease.